Document Detail


An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
MedLine Citation:
PMID:  16817333     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Bortezomib (Velcade), a novel proteasome inhibitor, has shown promise in the treatment of malignancies, including multiple myeloma and non-Hodgkin's lymphoma. Several studies have identified neuropathy as a potentially dose-limiting side effect of treatment with bortezomib. We report the clinical and electrodiagnostic data from four patients who developed signs and symptoms of peripheral neuropathy from treatment with bortezomib. MATERIALS AND METHODS: Patients were included if they were enrolled in active phase 2 trials of bortezomib for non-Hodgkin's lymphoma or prostate cancer, developed signs and symptoms of peripheral neuropathy, and were referred for electrodiagnostic evaluation. RESULTS: Four patients, including two with non-Hodgkin's lymphoma and two with prostate cancer, underwent electrodiagnostic testing. Electrodiagnostic evaluation showed pre-existing peripheral nervous system disorders in three out of four patients. Multiple peripheral nervous system disorders were present in two out of four patients. CONCLUSIONS: Bortezomib can cause a predominately sensory axonal polyneuropathy. Pre-existing peripheral nervous system disorders, such as neuropathy and radiculopathy, are common in patients with cancer, and may pre-dispose to the development of symptomatic neuronal toxicity when treated with bortezomib. Baseline electrodiagnostic evaluation may identify patients with pre-existing peripheral nervous system disorders at risk for additive neuronal toxicity from neurotoxic chemotherapeutic agents.
Authors:
M D Stubblefield; S Slovin; B MacGregor-Cortelli; J Muzzy; H Scher; J Wright; D Esseltine; D Schenkein; O A O'Connor
Related Documents :
14639583 - Atypical presentations of primary amyloid neuropathy.
7870113 - Comparison of the flexed and extended elbow positions in localizing ulnar neuropathy at...
16169633 - Dipeptidyl-peptidase iv in patients with short bowel syndrome.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical oncology (Royal College of Radiologists (Great Britain))     Volume:  18     ISSN:  0936-6555     ISO Abbreviation:  Clin Oncol (R Coll Radiol)     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-07-04     Completed Date:  2006-10-26     Revised Date:  2008-03-10    
Medline Journal Info:
Nlm Unique ID:  9002902     Medline TA:  Clin Oncol (R Coll Radiol)     Country:  England    
Other Details:
Languages:  eng     Pagination:  410-8     Citation Subset:  IM    
Affiliation:
Memorial Sloan-Kettering Cancer Center, Department of Neurology, Rehabilitation Medicine Service, New York, NY 10021, USA. stubblem@mskcc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Boronic Acids / therapeutic use*
Electrodiagnosis*
Female
Humans
Lymphoma, Non-Hodgkin / complications,  drug therapy
Male
Middle Aged
Peripheral Nervous System Diseases / diagnosis,  drug therapy*
Prostatic Neoplasms / complications,  drug therapy
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Grant Support
ID/Acronym/Agency:
U01 CA 69913/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Waiting times for cancer surgery in Ontario: 1984-2000.
Next Document:  Women's experience of termination of a pregnancy.